Pulmonx Q1 Revenue Falls 8.7% to $20.59M, Reports ($0.33) EPS
LUNG sits 18% above its 52-week low of $1.13.
Summary
Pulmonx Corp reported its first-quarter 2026 financial results, with revenue declining 8.7% year-over-year to $20.59 million and a net loss of ($0.33) per diluted share. This news summarizes the official 10-Q filing from earlier today, which also detailed a critical debt refinancing. While previous news on April 29th had indicated the revenue figure, the full official results including the EPS are now confirmed. The continued revenue decline and net loss highlight ongoing operational challenges for the company, despite efforts to improve gross margins and secure liquidity. Traders will be closely watching future revenue trends, product development progress, and the long-term impact of the recent debt refinancing on the company's financial stability.
At the time of this announcement, LUNG was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.2M. The 52-week trading range was $1.13 to $3.89. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.